Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Marshall Jonathan Urist - Executive Vice President of Research & Investments Pablo Gerardo Legorreta - Founder, Chairman of the Board & CEO Terrance P. Coyne - Executive VP & CFO Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Geoffrey Christopher Meacham - Citigroup Inc., Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline
Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment.
Royalty Pharma: Again, Guidance Raised, Buy Confirmed
Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, with a 2.6% dividend yield.
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and Vice Chairman Conference Call Participants Hardik Parikh - JPMorgan Mike Nedelcovych - TD Cowen Terence Flynn - Morgan Stanley Geoff Meacham - Citi Jason Gerberry - Bank of America Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago.
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
